Auburn Hills, Mich. Jan.8, 2014 — Donor Dialogue, a provider of products and services that assist in blood and plasma collection, has announced the signing of Grifols to its client portfolio. Donor Dialogue will supply Grifols with 24/7, bi-lingual contact center services for donors that have questions, concerns, suggestions and complaints associated with more than 140 plasma donor centers in the United States. Donor Dialogue will also provide the customer relationship management system, DRM Touch ®, to log and manage the call outcomes.
Grifols is a global healthcare company and leading producer of plasma therapies that treat people with rare, chronic and life-threatening conditions, such as immune deficiencies, hemophilia and genetic emphysema. To meet the growing demand for these life-saving plasma medicines, Grifols operates the largest network of plasma donor centers in the United States.
“The proven capabilities of Donor Dialogue's DRM Touch and our previous experience with their contact center services made our partnership decision easy,” states Amanda Mishler, Marketing Manager, Grifols Plasma Operations. “We are pleased to combine our passion and dedication for plasma donation with a partner that has been dedicated to this life-saving mission for nearly 30 years.”
“The teamwork between the Donor Dialogue's development team and Grifols project coordination team has been outstanding, allowing us to roll this system out on time and on budget,” says Doug Emig, president of Donor Dialogue. “This partnership will allow many people the convenience and ease of getting in contact with Grifols quickly, day or night.”
Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use. As a leading producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with more than 140 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.
In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com.